Jan 6 (Reuters) -
CANDID THERAPEUTICS ENTERS INTO AGREEMENT WITH WUXI BIOLOGICS ON TRISPECIFIC T-CELL ENGAGER
CANDID THERAPEUTICS - WUXI BIOLOGICS TO RECEIVE UP TO $925 MILLION IN PAYMENTS AND MILESTONES
CANDID - PLANS TO COMPLETE IND ENABLING STUDIES TO ENABLE FIRST-IN-HUMAN STUDIES IN FIRST HALF OF 2026
Source text: ID:nBw7pY2dZa
Further company coverage: 2269.HK
((Reuters.Briefs@thomsonreuters.com;))